Daily Endocrinology Research Analysis
Analyzed 36 papers and selected 3 impactful papers.
Summary
Top findings in endocrinology include: (1) integrative proteogenomic and clinical evidence nominating CXCL10 as a discriminative biomarker for latent autoimmune diabetes in adults (LADA); (2) urinary podocalyxin in youth with type 1 diabetes identifies a pre-albuminuric injury window and stratifies 12-year diabetic kidney disease risk; and (3) treatment-induced hypothyroidism after immune checkpoint inhibitors or radiotherapy correlates with improved survival, supporting its role as a prognostic biomarker.
Research Themes
- Biomarker discovery and validation in diabetes and autoimmunity
- Early risk stratification and kidney complication prevention in type 1 diabetes
- Endocrine-oncology interface: therapy-induced hypothyroidism as a prognostic signal
Selected Articles
1. Integrative proteogenomic and observational analysis identifies potential biomarkers for latent autoimmune diabetes in adults.
Proteome-wide MR and colocalization linked higher genetically predicted plasma CXCL10, SAA1, and SAA2 to increased LADA risk. CXCL10 showed the most robust evidence and demonstrated strong discrimination of LADA from T2D and healthy controls in a matched clinical cohort (ROC-AUC 0.838–0.889) with good calibration. Phenome-wide MR suggested no major safety concerns regarding CXCL10 as a biomarker/target.
Impact: This work couples causal inference (proteome-wide MR) with independent clinical validation, nominating CXCL10 as a translational biomarker to resolve LADA vs T2D ambiguity.
Clinical Implications: CXCL10 testing could improve early LADA recognition and guide appropriate therapy (e.g., earlier insulin, autoimmunity-focused management), but requires multi-ancestry, prospective validation before routine adoption.
Key Findings
- Proteome-wide MR identified CXCL10, SAA1, and SAA2 as proteins associated with increased LADA risk; CXCL10 had the strongest support.
- Colocalization, multi-tissue eQTL, and multivariable MR analyses reinforced the CXCL10–LADA association.
- In a matched clinical cohort (n=241), CXCL10 discriminated LADA from T2D and controls with ROC-AUC 0.838–0.889 and good calibration.
- Phenome-wide MR across 1,006 traits revealed no major safety concerns related to CXCL10 as a biomarker/target; druggability assessment supports ongoing target exploration.
Methodological Strengths
- Proteome-wide MR with cis-pQTLs and rigorous sensitivity/colocalization analyses for causal inference
- Independent observational validation with ELISA and discrimination/calibration metrics
Limitations
- MR discovery largely in European ancestry; observational validation in a single-center Chinese cohort
- Diagnostic cut-offs and clinical utility require prospective, multi-ethnic validation and head-to-head comparison with existing algorithms
Future Directions: Prospective, multi-ancestry validation of CXCL10-based diagnostic algorithms for LADA; evaluation of longitudinal dynamics and integration with islet autoantibodies and genetic risk scores.
BACKGROUND: Latent autoimmune diabetes in adults (LADA) shares core genetic and immunological features with type 1 diabetes (T1D) but is frequently misdiagnosed as type 2 diabetes (T2D). With few biomarkers for its timely diagnosis and management, this study integrated proteome-wide Mendelian randomisation (MR) and observational clinical analysis to identify potential LADA biomarkers. METHODS: We performed proteome-wide MR using cis-protein quantitative trait loci (cis-pQTLs) for 1,389 plasma proteins from the deCODE study (n = 35,559) and genome-wide association study (GWAS) data f
2. Survival Outcomes Associated with Hypothyroidism Following Cancer Therapies.
In 9,909 adults without prior thyroid disease receiving ICI, TKI, or radiotherapy, 22.0% developed hypothyroidism (median onset ~5 months). Treatment-induced hypothyroidism was associated with improved overall survival; benefit signals were strongest after ICI and radiotherapy.
Impact: Demonstrates prognostic value of an endocrine adverse event across therapies, supporting hypothyroidism as a real-world biomarker of therapeutic benefit.
Clinical Implications: Monitoring and managing thyroid function during ICI or radiotherapy may inform prognosis and patient counseling; hypothyroidism should not prompt premature discontinuation when otherwise manageable.
Key Findings
- Among 9,909 treated adults, 2,177 (22.0%) developed hypothyroidism, with median onset at 5.04 months.
- Treatment-induced hypothyroidism correlated with improved overall survival in time-dependent Cox models.
- Survival benefit signals were most evident following immune checkpoint inhibitors and radiotherapy.
- Findings persisted after adjustment for demographic, clinical, and lifestyle covariates.
Methodological Strengths
- Large, multi-therapy cohort with time-dependent exposure modeling
- Adjusted for multiple demographic, clinical, and lifestyle confounders with sensitivity analyses
Limitations
- Retrospective EHR design susceptible to residual confounding and indication/survivor bias
- Heterogeneity in thyroid function testing frequency and thresholds across therapies
Future Directions: Prospective studies to elucidate mechanisms linking antitumor immunity and thyroid autoimmunity, and to test whether thyroiditis/hypothyroidism can refine on-treatment response algorithms.
BACKGROUND: Hypothyroidism is a recognized adverse effect of cancer therapies such as immune checkpoint inhibitors (ICI), tyrosine kinase inhibitors (TKI), and radiotherapy. Although proposed as an indicator of treatment response, its prognostic significance across cancer types and therapies remains underexplored. This study evaluated survival outcomes associated with treatment-induced hypothyroidism. METHODS: We conducted a retrospective cohort study using de-identified electronic health record data fr
3. Urinary podocalyxin identifies a pre-albuminuric kidney injury window and stratifies 12-year diabetic kidney disease risk in youth with type 1 diabetes mellitus.
In youth with type 1 diabetes, baseline urinary podocalyxin/creatinine (u‑PCX/Cr) and other injury markers were elevated even with normoalbuminuria. Baseline u‑PCX/Cr strongly predicted 12-year incident DKD (AUC 0.96), with actionable thresholds (<78 ng/mgCr NPV 100%; ≥193 ng/mgCr specificity 95.5%).
Impact: Provides compelling long-term evidence that podocyte injury markers identify a pre-albuminuric injury window and outperform albuminuria for risk stratification in youth-onset T1D.
Clinical Implications: u‑PCX/Cr could complement spot u‑ACR for early DKD risk stratification and tailored surveillance in adolescents/young adults, pending external validation and cost-effectiveness analyses.
Key Findings
- At baseline, 90% had normoalbuminuria, yet u‑PCX/Cr, u‑nephrin/Cr, and u‑LFABP/Cr were elevated vs controls.
- Baseline u‑PCX/Cr predicted 12-year incident DKD with AUC 0.96 (95% CI 0.91–1.00).
- Risk thresholds for u‑PCX/Cr: <78 ng/mgCr (NPV 100%); 78–193 ng/mgCr (20% DKD incidence); ≥193 ng/mgCr (75% DKD incidence; specificity 95.5%).
- Spot u‑ACR also predicted DKD (AUC 0.87), but u‑PCX/Cr provided stronger discrimination and actionable cut-points.
Methodological Strengths
- Prospective 12-year follow-up with clinically meaningful endpoints
- Predefined biomarker thresholds with ROC-based performance and trend analyses
Limitations
- Small follow-up sample size (n=51) and single-center design limit generalizability
- Outcome defined by albuminuria; lacks eGFR decline/hard renal outcomes and external validation
Future Directions: External, multi-center validation; evaluation of combined biomarker panels with u‑ACR and integration into pediatric DKD screening algorithms.
BACKGROUND: Microalbuminuria indices may miss early diabetic kidney disease (DKD) and can regress. Urinary podocyte and tubular injury biomarkers may detect subclinical kidney injury before albuminuria. We evaluated urinary podocyte- and tubule-derived biomarkers in adolescents/young adults with type 1 diabetes mellitus (T1DM) and compared 12-year prognostic performance with albuminuria. METHODS: A total of 130 participants with T1DM were screened; 109 were eligible and included in the baseline ana